FindTrial
Sign In

Treatment of chronic renal insufficiency and its complications

Treatment of chronic renal insufficiency and its complications

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018712
Enrollment
Unknown
Registered
2018-10-05
Start date
2013-01-01
Completion date
Unknown
Last updated
2018-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic renal failure

Interventions

Group 1:Prostaglandin E1
Group 2:Shenkang/Shenkang+Prostaglandin E1

Sponsors

Shanghai Tenth People's Hospital, Tongji University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients or their legal representatives provided written informed consent. CKD patients treated with Prostaglandin E1 or/and Shenkang injection, admitted to Shanghai Tenth Peoples Hospital, Tongji University School of Medicine between January 2013 and December 2017, were recruited in this study.

Exclusion criteria

Exclusion criteria: Exclusion criteria included acute acute kidney injury, renal replacement treatment, cancer, a malignant hematopoietic system, chronic heart failure, gastrointestinal ulcer, severe liver damage, pregnacy, and immunosuppressive agent.

Design outcomes

Primary

MeasureTime frame
renal function;—

Secondary

MeasureTime frame
Proteinuria;blood fat;inflammation;—

Countries

China

Contacts

Public ContactWang Zhen

Shanghai Tenth People's Hospital, Tongji University School of Medicine

wang.zhen@tongji.edu.cn+86 15901989527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026